<DOC>
	<DOCNO>NCT00678015</DOCNO>
	<brief_summary>This Phase II , single center study measure pharmacokinetic parameter NDGA administration assess proportion patient experience 50 % decline PSA .</brief_summary>
	<brief_title>Pharmacokinetic Efficacy Study Nordihydroguaiaretic Acid ( NDGA ) Non Metastatic Recurrent Prostate Cancer</brief_title>
	<detailed_description>This study phase II trial NDGA patient hormone-sensitive non-metastatic prostate cancer pharmacokinetics component . The first six patient enrol treat single 750 mg dose oral NDGA day -7 measurement pharmacokinetic parameter eight hour dose , begin treatment 2000 mg oral NDGA daily . Every four week , measurement pharmacokinetic parameter steady state do patient . All patient continue dose NDGA follow PSA response safety . Measurement pharmacokinetics 750 mg dose chosen evaluate level dosage patient take one time point day ( roughly one-third daily dose , administer three divided dos ) .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Masoprocol</mesh_term>
	<criteria>Rising prostatespecific antigen ( PSA ) value local therapy PSA doubling time ( PSADT ) 6 24 month ( four reading least two week apart within last six month ) Prior definitive therapy prostate cancer consist one following : 1 . External beam radiotherapy without hormone therapy 2 . Brachytherapy without pelvic external beam radiation hormone therapy 3 . Radical prostatectomy without adjuvant salvage radiation therapy PSA &gt; 1 ng/ml , rise serially two determination least one week apart Progressive disease `` Phoenix '' consensus definition patient undergone primary radiation therapy ( PSA nadir + 2 ng/mL ) No metastatic disease Prior adjuvant neoadjuvant androgen deprivation permit , provide : 1 . &gt; 6 month since last day effective androgen deprivation 2 . Testosterone &gt; 250 ng/dL 3 . Patient intermittent androgen deprivation Karnofsky performance status ( KPS ) &gt; 70 % Liver Function Tests within normal range Glycated hemoglobin ( HgA1c ) &lt; 6 % Patients must four week major surgery radiotherapy eligible Presence another active malignancy prostate cancer , treat squamous/basal cell carcinoma skin . Concomitant medical condition would make undesirable , physician 's opinion , patient participate protocol would jeopardize compliance protocol requirement Diabetes mellitus , unless dietcontrolled Must saw palmetto , pomegranate juice , finasteride , herbal agent intend low PSA &gt; 4 week . Baseline PSADT calculation must occur agent Patients may evidence localonly recurrence prostate cancer No history liver disease , include Hepatitis B C , alcoholic liver disease , autoimmune liver disease . A prior history Hepatitis A allow provided baseline liver function test within normal limit Patients castration resistant prostate cancer ineligible ( prostate cancer progress androgen deprivation therapy Luteinizing hormonereleasing hormone ( LHRH ) agonist orchiectomy )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>NDGA</keyword>
	<keyword>Prostate Cancer</keyword>
</DOC>